Price is $2.2 million per NYTimes: https://web.archive.org/web/20231214145621/https://www.nytimes.com/2023/12/08/health/fda-sickle-cell-crispr.html
So the number of treatments to reach that would actually be quite small. But the article also notes that the capacity will be extremely limited. Vertex has 9 centers approved to offer the treatment, and one of those says they can treat 5-10 a year.
$100 million seems like the right ballpark, and I think the chance they hit that in 2025 seems reasonably high, but for 2024 I'm not optimistic unless the figures from the NYTimes don't tell the full story or I am misreading them.